Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

Presentation TCT 2024

TCT 185: Clinical Outcomes of SGLT2 Inhibitors Among Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair

Presenter: Samarthkumar Thakkar

October 27, 2024

Presentation ESC 2024

Continuation versus Interruption of Oral Anticoagulation during TAVI

Presenter: Dirk-Jan van Ginkel

August 31, 2024

Presentation TCT 2023

TCT 436: Outcomes of Renin-Angiotensin Inhibitors following Transcatheter Aortic Valve Implantation

Presenter: Rahul Gupta

October 26, 2023

Presentation TCT 2023

TCT 378: A novel miRNA nanocarrier for local device-based pharmacotherapy

Presenter: Stephanie Bettink

October 26, 2023

Presentation TCT 2023

TCT 146: Retrospective Analysis of High-Grade Atrioventricular Block in TAVR Patients Prescribed Philips Mobile Cardiac Outpatient Telemetry

Presenter: CJ Grigoriadis

October 26, 2023

Presentation TCT 2023

TCT 30: Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

Presenter: Byeong-Keuk Kim

October 25, 2023

Presentation TVT 2022

Pharmacologic "Protection" to Reduce Strokes After TAVR: Current Evidence and Recommendations

Presenter: George Dangas

June 10, 2022

Presentation TVT 2022

What's best for my patient when it comes to their post-implant drug regimen?

Presenter: Megan Coylewright

June 10, 2022

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation

RAS Inhibition Following TAVR

July 29, 2019

Presentation TCT 2017

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Presenter: Eberhard Grube, James B. Hermiller Jr., Pascal Vranckx

November 01, 2017

Presentation TCT 2017

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

Presenter: Samir R. Kapadia

November 01, 2017

Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve The ARTE Randomized Clinical Trial

Presentation EuroPCR 2017

The ARTE Randomized Clinical Trial

Presenter: Josep Rodés-Cabau

May 17, 2017

Presentation TCT 2016

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Presenter: Raj Makkar, Lars Sondergaard, Davide Capodanno

October 31, 2016

Presentation TCT 2016

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Presenter: A. Pieter Kappetein, Allan Schwartz, Samir R. Kapadia

October 30, 2016

Advertisement

TCT 185: Clinical Outcomes of SGLT2 Inhibitors Among Patients Undergoing Mitral Transcatheter Edge-to-Edge Repair

Continuation versus Interruption of Oral Anticoagulation during TAVI

TCT 436: Outcomes of Renin-Angiotensin Inhibitors following Transcatheter Aortic Valve Implantation

TCT 378: A novel miRNA nanocarrier for local device-based pharmacotherapy

TCT 146: Retrospective Analysis of High-Grade Atrioventricular Block in TAVR Patients Prescribed Philips Mobile Cardiac Outpatient Telemetry

TCT 30: Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

Pharmacologic "Protection" to Reduce Strokes After TAVR: Current Evidence and Recommendations

What's best for my patient when it comes to their post-implant drug regimen?

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

RAS Inhibition Following TAVR

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Managing AS Patients With Atrial Fibrillation in TAVR Patients Pharmacotherapy Considerations and LAAC Possibilities (WATCH-TAVR Trial)

The ARTE Randomized Clinical Trial

Updates on New Adjunctive Pharmacotherapy Clinical Trials for TAVR

Aortic Stenosis + Concomitant Disease III. TAVR in Patients With Atrial Fibrillation - Outcomes, Adjunctive Pharmacology, and Accessory Therapies (Including LAA Closure)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content